Mercaptopurine for HLRCC-related kidney cancer, fibroids, and skin bumps
Treatments studied
Part of Cancer, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether the drug mercaptopurine can shrink tumors or reduce symptoms in people with HLRCC, a genetic condition that causes kidney cancer, uterine fibroids, and painful skin bumps. The study looks at the drug's effect on each of these three problems separately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years of age or older.
- You must have a genetic change (mutation) in the FH gene – either known to cause disease, or a variant that is linked to loss of FH function.
- You must have one of these conditions: advanced kidney cancer, symptomatic uterine fibroids (with heavy bleeding or pelvic pain), or at least 5 painful skin bumps (leiomyomas).
- Your liver and kidney function must be within acceptable limits (based on blood tests).
- You must have a normal version of enzymes that process thiopurine drugs (like mercaptopurine) – this is tested by a blood test before enrollment.
- If you are having uterine fibroids, you must not have used certain hormone treatments recently and must agree to use non-hormonal birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a new drug, INCA033989, alone or with ruxolitinib for people with certain blood cancers called myeloproliferative neoplasms (MPNs). It may help those with a specific genetic change (CALR mutation) who have not had success with other treatments.
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
This trial tests a new drug called Purinostat Mesylate, either alone or combined with other drugs, in people with advanced solid tumors (including breast cancer) that have not responded to standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
Hear when a new Advanced Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.